comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 20:16:22 - browse：644

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA proposes changes to key medical devices approval pathway

explore

WSS

Quicker fix for pulse oximeters urged during FDA public meeting

Cybersecurity threat forces Lurie Children's to take systems offline

WATCH: Why do bright lights make us see spots?

How housing is health care on Long Island

Biden administration opens offers in Medicare drug price negotiations

Diverse clinical trials: Why aren’t we there yet?

Wikipedia

comprehensive

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

New weight loss drugs vying to be the next Wegovy or Mounjaro

Supreme Court strikes down use of affirmative action

Food makers to regulators: Ultra

Medicare proposal to cover medical devices draws a mixed reaction

Juul spent big to court Black leaders to promote its e

Hepatitis C has a cure — but many Americans still lack access to it

How medical schools plan to diversify without affirmative action

Medicare proposal to cover medical devices draws a mixed reaction

FDA approves updated Covid vaccines

focus

Popular nasal decongestant doesn't actually relieve congestion

Some dementia cases could be undiagnosed liver disease

Telehealth for opioid use disorder is lifesaving

FDA panel endorses Alnylam’s heart drug — after picking it apart

Do digital therapeutics have a future in medicine?

ARCH Venture Partners is raising $3 billion for a life sciences fund

focus

explore

hotspot

entertainment